GFA
NTLA icon

Gallagher Fiduciary Advisors’s Intellia Therapeutics NTLA Stock Holding History

Gallagher Fiduciary Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$198K Buy
11,683
+32
+0.3% +$448 0.01% 354
2026
Q1 		$149K Buy
+11,651
New +$148K 0.01% 326

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Gallagher Fiduciary Advisors's NTLA Position: Q2 2026 in Review

Gallagher Fiduciary Advisors increased its Intellia Therapeutics (NTLA) stake by 0.27% in Q2 2026, buying an estimated $448 and bringing the position to 11,683 shares worth $198K. The position accounts for 0.01% of the portfolio, ranked #354.

Gallagher Fiduciary Advisors first reported a position in NTLA in Q1 2026 and has held it in 2 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Gallagher Fiduciary Advisors held 11,683 shares of Intellia Therapeutics worth $198K as of Q2 2026.
  • Gallagher Fiduciary Advisors bought 32 Intellia Therapeutics shares in Q2 2026, an estimated $448.
  • Intellia Therapeutics made up 0.01% of Gallagher Fiduciary Advisors's portfolio in Q2 2026, its #354 holding.
  • Gallagher Fiduciary Advisors first reported a position in Intellia Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Gallagher Fiduciary Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.